The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained’ ...

Research by the authors on CHIKV is supported by NIH grants AI069145, AI082202, AI093491 and by a grant from the National Institute of Allergy and Infectious Disease (NIAID) through the Western ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first ...

Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

Chikungunya is a disease that is caused by the chikungunya virus which is transmitted to humans by infected mosquitoes. Its name is derived from a word in the Makonde language that means contorted or ...

The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...